Cancer BiologyClinical Cancer ResearchPeer-reviewed
COMBINATION THERAPIES TARGETING ALK-ABERRANT NEUROBLASTOMA IN PRECLINICAL MODELS.
E. Tucker, I. Jimenez, L. Chen…·G. Schleiermacher
This study evaluates lorlatinib, an ALK inhibitor, in combination with chemotherapy or idasanutlin in preclinical neuroblastoma models, finding synergy in models with high ALK expression.
DOI 10.1158/1078-0432.ccr-22-2274